| 期刊簡介 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Blood Cancer Journal LetPub Score 8.3
50 ratings
Rate
Reputation 9.5 Influence 7.6 Speed 7.0 | ||||||||||||||||||||
| 期刊簡稱 | BLOOD CANCER J | ||||||||||||||||||||
| ISSN | 2044-5385 | ||||||||||||||||||||
| h-index | 37 | ||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||
| 自引率 (2023-2024) | 2.30%自引率趨勢 | ||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||
| 官方網站 | http://www.nature.com/bcj | ||||||||||||||||||||
| 在線稿件提交 | http://mts-bcj.nature.com/cgi-bin/main.plex | ||||||||||||||||||||
| 開放訪問 | Yes | ||||||||||||||||||||
| 出版商 | Springer Nature | ||||||||||||||||||||
| 主題領域 | ONCOLOGY | ||||||||||||||||||||
| 出版國/地區 | ENGLAND | ||||||||||||||||||||
| 發行頻率 | |||||||||||||||||||||
| 創刊年 | 2011 | ||||||||||||||||||||
| 每年文章數 | 99每年文章數趨勢 | ||||||||||||||||||||
| 黃金OA百分比 | 99.68% | ||||||||||||||||||||
OA Related Info | APC: Yes（ GBP3390; USD4990; EUR3890; ） APC waiver：Check Notes Other charges: No Keywords: hematologic malignancies、blood cancer、immunology Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||||||
| Web of Science 四分位 （ 2023-2024） | WOS Quartile: Q1
| ||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2044-5385%5BISSN%5D | ||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: >12 Week(s), or Invited contributions | ||||||||||||||||||||
| 競爭力 * | 來自作者的數據: Easy | ||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||
| *所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||
|
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [Blood Cancer Journal] 的評論 | 撰寫評論 |
| 作者: 舒兰小仙女 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2023-10-13 23:17:38 評論於 Excuse me, I couldn't find the requirements for the case on the official website  (0) 讚！ | 舒兰小仙女  |
| 作者: 舒兰小仙女 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2023-10-13 13:55:13 評論於 How are you? I couldn't find the case requirements on the official website (0) 讚！ | 舒兰小仙女 |
| 作者: 龙象诗晗 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2023-09-17 23:11:14 評論於 I just prepared to shoot, but it seems like I missed. Hahaha (0) 讚！ | 龙象诗晗 |
| 作者: 忻慕君 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2023-04-01 14:34:15 評論於 Can I ask if this magazine accepts case reports? (0) 讚！ | 忻慕君 |
| 作者: 黑山韶阳 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-09-22 17:47:46 評論於 What is the status of external review after submitting the manuscript for review, thank you (0) 讚！ | 黑山韶阳 |
| 作者: 凤凰院鸿达 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-05-11 08:59:53 評論於 May I ask what the status of the submission is? It has been "Under Consideration" since submission (0) 讚！ | 凤凰院鸿达 |
| 作者: 一条小淑静 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-03-31 23:09:50 評論於 Review Speed: 1.0 | Submission Acceptance Rate: 50.0 Experience Sharing: The speed is very fast, submitted for review the next day after submission, and received review comments from external reviewers after 3 weeks. It feels like the requirements are much stricter for Chinese researchers. It took 4 months for major revisions, including adding animal experiments, but the paper was accepted quickly after revisions (0) 讚！ | 一条小淑静 |
| 作者: 特里斯塔斯克里普斯 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2018-06-16 10:44:02 評論於 I once submitted an article, but I suggest that it be published as a letter. I want to publish the full text. The Chinese people's mindset still needs to change a little! (0) 讚！ | 特里斯塔斯克里普斯 |
| 作者: 菩提梦寒 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2017-09-14 22:18:13 評論於 Growing rapidly, very promising (0) 讚！ | 菩提梦寒 |
| 作者: 留云鑫平 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2015-06-19 21:48:29 評論於 Review Speed: 1.0 | Submission Acceptance Rate: 25.0 Experiences Shared: What does "Manuscript Withdrawn" mean? (0) 讚！ | 留云鑫平 |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2014-09-02 18:23:36 評論於 Blood Cancer Journal seeks to publish articles of the highest quality related to hematologic malignancies and related disorders. The Journal will consider for publication original research, reviews, guidelines and letters that are considered to be of high impact in the field. The standard is acceptable, but there are very few papers published domestically, and the Journal's reputation is not that high (0) 讚！ | 凌霄高洁 |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us
